Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04382664
Title UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ultimovacs ASA



Ipilimumab + Nivolumab

Ipilimumab + Nivolumab + Sargramostim + UV1 Telomerase peptide vaccine

Age Groups: adult | senior
Covered Countries USA | BEL

No variant requirements are available.